TABLE OF CONTENTS
1 INTRODUCTION 9
1.1 OBJECTIVES OF THE STUDY 9
1.2 MARKET DEFINITION 9
1.3 OVERVIEW OF INDIA CORD STEM CELL BANKING MARKET 10
1.4 LIMITATIONS 11
1.5 MARKETS COVERED 11
2 MARKET SEGMENTATION 13
2.1 MARKETS COVERED 13
2.2 YEARS CONSIDERED FOR THE STUDY 14
2.3 CURRENCY AND PRICING 14
2.4 DBMR TRIPOD DATA VALIDATION MODEL 15
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 18
2.6 DBMR MARKET POSITION GRID 19
2.7 MULTIVARIATE MODELING 21
2.8 SECONDARY SOURCES 22
2.9 ASSUMPTIONS 22
3 MARKET OVERVIEW 23
3.1 DRIVERS 25
3.1.1 INCREASING BIRTH RATE 25
3.1.2 INCREASING PREVALENCE OF BETA-THALASSEMIA AND OTHER DISORDERS 26
3.2 RESTRAINT 26
3.2.1 HIGH COST FOR PRESERVATION IN BANKS 26
3.3 OPPORTUNITIES 27
3.3.1 SCOPE OF CORD STEM CELL BANKING IN INDIAN MARKET 27
3.3.2 AVAILIBILTY OF VARIOUS TECHNOLOGIES FOR BLOOD PROCESSING 27
3.4 CHALLENGE 28
3.4.1 LACK OF FUNDS 28
4 EXECUTIVE SUMMARY 29
5 PREMIUM INSIGHTS 32
6 INDIA CORD STEM CELL BANKING MARKET, BY SOURCE 33
6.1 OVERVIEW 34
6.2 UMBILICAL CORD 35
6.2.1 HEMATOPOIETIC CELLS 35
6.2.2 MESENCHYMAL CELLS 35
6.3 PLACENTA 35
6.4 AMNIOTIC SAC 35
6.5 AMNIOTIC FLUID 35
7 INDIA CORD STEM CELL BANKING MARKET, BY APPLICATION 36
7.1 OVERVIEW 37
7.2 BLOOD DISORDERS/BONE MARROW FAILURE 38
7.3 CANCERS 38
7.3.1 LEUKAEMIA 38
7.3.2 LYMPHOMAS 38
7.3.3 MYELOMAS 38
7.3.4 MYELOPROLIFERATIVE NEOPLASMS 38
7.3.5 NEUROBLASTOMA 38
7.3.6 OTHER BLOOD CANCERS 39
7.4 NEUROLOGIC DISORDERS 39
7.5 GENETIC DISORDER 39
7.6 METABOLIC DISORDERS 39
7.6.1 KRABBE DISEASE 39
7.6.2 HURLER SYNDROME 39
7.6.3 OTHERS 39
7.7 IMMUNE DISORDERS 39
7.8 OTHERS 40
8 INDIA CORD STEM CELL BANKING MARKET, BY MODE OF TREATMENT 41
8.1 OVERVIEW 42
8.2 AUTOLOGOUS 43
8.3 ALLOGENEIC 43
9 INDIA CORD STEM CELL BANKING MARKET, BY SERVICE TYPE 44
9.1 OVERVIEW 45
9.2 SAMPLE PRESERVATION AND STORAGE 46
9.3 SAMPLE PROCESSING 46
9.4 SAMPLE ANALYSIS 46
9.5 SAMPLE COLLECTION AND TRANSPORTATION 46
10 INDIA CORD STEM CELL BANKING MARKET, BY CORD BLOOD BANKING 47
10.1 OVERVIEW 48
10.2 PRIVATE CORD BLOOD BANKS 49
10.3 PUBLIC CORD BLOOD BANKS 49
11 INDIA CORD STEM CELL BANKING MARKET, COMPANY LANDSCAPE 50
11.1 COMPANY SHARE ANALYSIS: INDIA 50
12 SWOT ANALYSIS 51
12.1 STRENGTH: - ESTABLISHED PRESENCE IN MARKETS 51
12.2 WEAKNESS: - LACK OF TECHNOLOGICAL ADVANCEMENT 51
12.3 OPPORTUNITY: - STRATEGIC ACQUISITIONS/ PARTNERSHIPS 51
12.4 THREAT: - LACK OF FUNDS 52
12.5 DATA BRIDGE MARKET RESEARCH ANALYSIS 52
13 COMPANY PROFILES 53
13.1 LIFECELL 53
13.1.1 COMPANY SNAPSHOT 53
13.1.2 SERVICE PORTFOLIO 53
13.1.3 RECENT DEVELOPMENTS 53
13.2 CORDLIFE 54
13.2.1 COMPANY SNAPSHOT 54
13.2.2 REVENUE ANALYSIS 54
13.2.3 SERVICE PORTFOLIO 55
13.2.4 RECENT DEVELOPMENTS 56
13.3 GLOBAL CORD BLOOD CORPORATION 57
13.3.1 COMPANY SNAPSHOT 57
13.3.2 REVENUE ANALYSIS 57
13.3.3 SERVICE PORTFOLIO 58
13.3.4 RECENT DEVELOPMENT 59
13.4 STEMCYTE INDIA THERAPEUTICS PVT. LTD (A SUBSIDIARY OF STEMCYTE) 60
13.4.1 COMPANY SNAPSHOT 60
13.4.2 SERVICE PORTFOLIO 60
13.4.3 RECENT DEVELOPMENT 60
13.5 REGROW BIOSCIENCES PVT LTD 61
13.5.1 COMPANY SNAPSHOT 61
13.5.2 SERVICE PORTFOLIO 61
13.5.3 RECENT DEVELOPMENT 61
13.6 RELIANCE LIFE SCIENCES LTD. 62
13.6.1 COMPANY SNAPSHOT 62
13.6.2 SERVICE PORTFOLIO 62
13.6.3 RECENT DEVELOPMENTS 62
13.7 CRYOVIVA INDIA 63
13.7.1 COMPANY SNAPSHOT 63
13.7.2 SERVICE PORTFOLIO 63
13.7.3 RECENT DEVELOPMENT 64
?
13.8 INTERNATIONAL STEMCELL SERVICES LTD. 65
13.8.1 COMPANY SNAPSHOT 65
13.8.2 SERVICE PORTFOLIO 65
13.8.3 RECENT DEVELOPMENT 65
13.9 MYCORD (A SUBSIDIARY OF CELLUGEN BIOTECH PVT. LTD.) 66
13.9.1 COMPANY SNAPSHOT 66
13.9.2 SERVICE PORTFOLIO 66
13.9.3 RECENT DEVELOPMENTS 66
13.10 REELABS PVT. LTD. 67
13.10.1 COMPANY SNAPSHOT 67
13.10.2 SERVICE PORTFOLIO 67
13.10.3 RECENT DEVELOPMENT 67
14 CONCLUSION 68
15 QUESTIONNAIRE 69
16 RELATED REPORTS 72